The US FDA'S decision not to grant immediate approval to fresh generic versions of Norvasc is a big setback to India’s copycat drugmakers.
Section: Money | Thursday, April 19, 2007 23:34 IST
The going seems to be getting tougher by the day for Indian pharmaceutical companies looking to strike gold in the US generics market.
Section: Money | Wednesday, April 11, 2007 22:28 IST
The global contract research and manufacturing services (CRAMS) market was estimated at $13 billion in 2005. It has a CAGR of 14% (2005-09).
Section: Money | Wednesday, April 11, 2007 21:28 IST
Strides Arcolab, which is keen to acquire the Chennai-based Grandix Pharmaceuticals Ltd, is mainly eyeing the domestic pharmaceuticals market through the buyout.
Section: Money | Tuesday, April 10, 2007 22:18 IST
The move assumes significance in the backdrop of the case filed by Novartis against Section 3 (d) of Indian Patent Act.
Section: Money | Monday, April 2, 2007 22:32 IST
Though Pfizer’s basic patent on Liptor expires only in 2011, Ranbaxy's been hoping to sell the drug in the US from 2010, the year salt patent of Pfizer expires.
Section: Money | Thursday, March 29, 2007 23:31 IST
USV Limited, a leading player in the domestic diabetes and cardiovascular drug segment, is eyeing tie-ups with local companies to expand its presence in Latin America.
Section: Money | Thursday, March 29, 2007 21:26 IST
Glenmark is looking for more investment in the acquired facility and will also launch more speciality products in the $1.5-billion Czech Republic market.
Section: Money | Monday, March 26, 2007 22:13 IST
Concerns have been raised over Drug Eluting Stent (DES), a device using to remove blockage to the artery in cardiac patients, forcing a rethink among cardiologists about its use.
Section: Money | Friday, March 23, 2007 22:40 IST
A leading player in India’s bulk drug business, Shasun has entered into several tie-ups with US companies as part of diversifying its business.
Section: Money | Friday, March 23, 2007 22:07 IST
|
Archive page 1 of 15 |
 |
